Urien L, Jauregizar N, Lertxundi U, Fernández U, Morera-Herreras T. Medication impact on oral health in schizophrenia. Med Oral Patol Oral Cir Bucal. 2024 Jan 1;29 (1):e51-7.
doi:10.4317/medoral.26061
https://dx.doi.org/doi:10.4317/medoral.26061
1. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119-36. |
PMid:26043321 PMCid:PMC4471960 |
2. Arnaiz A, Zumárraga M, Díez-Altuna I, Uriarte JJ, Moro J, Pérez-Ansorena MA. Oral health and the symptoms of schizophrenia. Psychiatry Res. 2011;188:24-8. |
PMid:21055830 |
3. Denis F, Milleret G, Wallenhorst T, Carpentier M, Rude N, Trojak B. Oral health in schizophrenia patients: A French Multicenter Cross-Sectional Study. Presse Med. 2019;48:e89-e99. |
PMid:30853291 |
4. Hu KF, Ho PS, Chou YH, Tsai JH, Lin CR, Chuang HY. Periodontal disease and effects of antipsychotic medications in patients newly diagnosed with schizophrenia: a population-based retrospective cohort. Epidemiol Psychiatr Sci. 2019;29:e49. |
PMid:31526409 PMCid:PMC8061124 |
5. Chu KY, Yang NP, Chou P, Chiu HJ, Chi LY. Comparison of oral health between inpatients with schizophrenia and disabled people or the general population. J Formos Med Assoc. 2012;111:214-9. |
PMid:22526210 |
6. Wey MC, Loh S, Doss JG, Abu Bakar AK, Kisely S. The oral health of people with chronic schizophrenia: A neglected public health burden. Aust N Z J Psychiatry. 2016;50:685-94. |
PMid:26560842 |
7. Chapple IL. The impact of oral disease upon systemic health-Symposium overview. J Dent. 2009;37:S568-71. |
PMid:19501447 |
8. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589-608. |
PMid:9853791 |
9. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 2006; 8:99-105. |
PMid:16754415 |
10. Velasco-Ortega E, Monsalve-Guil L, Ortiz-Garcia I, Jimenez-Guerra A, Lopez-Lopez J, Segura-Egea JJ. Dental caries status of patients with schizophrenia in Seville, Spain: a case-control study. BMC Res Notes. 2017;10:50. |
PMid:28100262 PMCid:PMC5241932 |
11. Bertaud-Gounot V, Kovess-Masfety V, Perrus C, Trohel G, Richard F. Oral health status and treatment needs among psychiatric inpatients in Rennes, France: a cross-sectional study. BMC Psychiatry. 2013;13:227. |
PMid:24053587 PMCid:PMC3856526 |
12. Velasco E, Machuca G, Martinez-Sahuquillo A, Rios V, Lacalle J, Bullón P. Dental health among institutionalized psychiatric patients in Spain. Spec Care Dentist. 1997;17:203-6. |
PMid:9791299 |
13. Ramon T, Grinshpoon A, Zusman SP, Weizman A. Oral health and treatment needs of institutionalized chronic psychiatric patients in Israel. Eur Psychiatry. 2003;18:101-5. |
PMid:12763294 |
14. Đorđević V, Jovanović M, Miličić B, Stefanović V, Đukić-Dejanović S. Prevalence of dental caries in hospitalized patients with schizophrenia. Vojnosanit Pregl. 2016;73:1102-8. |
PMid:29341566 |
15. Friedlander AH, Marder SR. The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc. 2002;133:603-10. |
PMid:12036166 |
16. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809-20. |
PMid:16298220 |
17. Phipps KR, Stevens VJ. Relative contribution of caries and periodontal disease in adult tooth loss for an HMO dental population. J Public Health Dent. 1995;55:250-2. |
PMid:8551465 |
18. Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. Behav Brain Res. 2021;404:113168. |
PMid:33581145 |
19. Immadisetty V, Agrawal P. A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review. Therapeutic Advances in Psychopharmacology. 2012;2:235-9. |
PMid:23983982 PMCid:PMC3736957 |
20. Friedlander AH, Liberman RP. Oral health care for the patient with schizophrenia. Spec Care Dentist. 1991;11:179-83. |
PMid:1839864 |
21. Grisso T, Appelbaum PS. Comparison of standards for assessing patients' capacities to make treatment decisions. Am J Psychiatry. 1995;152:1033-7. |
PMid:7793439 |
22. Zeng LN, Zong QQ, Zhang L, Feng Y, Ng CH, Ungvari GS, et al. Worldwide prevalence of smoking cessation in schizophrenia patients: A meta-analysis of comparative and observational studies. Asian J Psychiatr. 2020;54:102190. |
PMid:32622029 |
23. Joshi YB, Thomas ML, Hochberger WC, Bismark AW, Treichler EBH, Molina J, et al. Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients. Schizophr Res. 2019;208:384-9. |
PMid:30738698 PMCid:PMC8215853 |
24. Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2021;178:838-47. |
PMid:33985348 PMCid:PMC8440496 |
25. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055-62. |
PMid:19570929 PMCid:PMC3735363 |
26. Bengtsson J, Olsson E, Igelström H, Persson J, Bodén R. Ambulatory Heart Rate Variability in Schizophrenia or Depression: Impact of Anticholinergic Burden and Other Factors. J Clin Psychopharmacol. 2021;41:121-8. |
PMid:33605645 PMCid:PMC7919703 |
27. Chapuis J, Siu-Paredes F, Pavageau C, Amador G, Rude N, Denis F. Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with Schizophrenia: A Pilot Study. Transl Neurosci. 2020;11:10-6. |
PMid:32104590 PMCid:PMC7029653 |
28. Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69:1485-96. |
PMid:23529548 |
29. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13:17-24. |
PMid:23551407 |
30. Tristancho-Pérez Á, Villalba-Moreno Á, Santos-Rubio MD, Belda-Rustarazo S, Santos-Ramos B, Sánchez-Fidalgo S. Concordance Among 10 Different Anticholinergic Burden Scales in At-Risk Older Populations. J Patient Saf. 2022;18:e816-e21 |
PMid:34693926 PMCid:PMC9162063 |
31. Villalba-Moreno Á, Alfaro-Lara ER, Sánchez-Fidalgo S, Nieto-Martín MD, Santos-Ramos B. Development of the Anticholinergic Burden Calculator Web Tool. Farm Hosp. 2017;41:647-8. |
PMid:28847259 |
32. Carramolino-Cuéllar E, Lauritano D, Silvestre FJ, Carinci F, Lucchese A, Silvestre-Rangil J. Salivary flow and xerostomia in patients with type 2 diabetes. J Oral Pathol Med. 2018;47:526-30. |
PMid:29604122 |
33. Vernillo AT. Dental considerations for the treatment of patients with diabetes mellitus. J Am Dent Assoc. 2003;134:24S-33S. |
PMid:18196670 |
34. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-8. |
PMid:29555994 PMCid:PMC6108420 |
35. Amaral L, Viveiros M, Molnar J. Antimicrobial activity of phenothiazines. In Vivo. 2004.18:725-31. |
PMid:15646813 |
36. Escudero J, Muñoz JL, Morera-Herreras T, Hernandez R, Medrano J, Domingo-Echaburu S, et al. Antipsychotics as environmental pollutants: An underrated threat?. Sci Total Environ. 2021;769:144634. |
PMid:33485196 |
37. Caldara M, Marmiroli N. Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications. Pharmaceuticals (Basel). 2021;14:915. |
PMid:34577614 PMCid:PMC8470654 |
38. AlmståhI A, Wikström M, Stenberg I, Jakobsson A, Fagerberg-Mohlin B. Oral microbiota associated with hyposalivation of different origins. Oral Microbiol Immunol. 2003;18:1-8. |
PMid:12588452 |